Movement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock

Market Focus06-02

On June 2, Revolution Medicines rose 5.11% in regular trading, trading at approximately $165.45/share, with trading volume of $7.53 billion. The stock continued its upward momentum following landmark Phase 3 clinical data presented at the ASCO annual meeting.

The company's pivotal RASolute 302 trial enrolled 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. Results showed daraxonrasib doubled median overall survival to 13.2 months versus 6.6 months for chemotherapy, while progression-free survival improved from 3.5 to 7.3 months. The data was simultaneously published in The New England Journal of Medicine. This marks the first time a second-line pancreatic cancer therapy has extended median OS beyond one year, representing a milestone breakthrough in RAS-targeted therapy.

Oppenheimer raised its price target from $165 to $195 while maintaining an Outperform rating. The analyst consensus mean target stands at $184.29 with an average Buy rating. The company is also advancing daraxonrasib into first-line treatment and combination therapy trials, broadening its commercial outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143599581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 02:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143599581","market":"us","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock","media":"Market Focus","content":"<p><p>On June 2, Revolution Medicines rose 5.11% in regular trading, trading at approximately $165.45/share, with trading volume of $7.53 billion. The stock continued its upward momentum following landmark Phase 3 clinical data presented at the ASCO annual meeting.</p><p>The company's pivotal RASolute 302 trial enrolled 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. Results showed daraxonrasib doubled median overall survival to 13.2 months versus 6.6 months for chemotherapy, while progression-free survival improved from 3.5 to 7.3 months. The data was simultaneously published in The New England Journal of Medicine. This marks the first time a second-line pancreatic cancer therapy has extended median OS beyond one year, representing a milestone breakthrough in RAS-targeted therapy.</p><p>Oppenheimer raised its price target from $165 to $195 while maintaining an Outperform rating. The analyst consensus mean target stands at $184.29 with an average Buy rating. The company is also advancing daraxonrasib into first-line treatment and combination therapy trials, broadening its commercial outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-02 02:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, Revolution Medicines rose 5.11% in regular trading, trading at approximately $165.45/share, with trading volume of $7.53 billion. The stock continued its upward momentum following landmark Phase 3 clinical data presented at the ASCO annual meeting.</p><p>The company's pivotal RASolute 302 trial enrolled 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. Results showed daraxonrasib doubled median overall survival to 13.2 months versus 6.6 months for chemotherapy, while progression-free survival improved from 3.5 to 7.3 months. The data was simultaneously published in The New England Journal of Medicine. This marks the first time a second-line pancreatic cancer therapy has extended median OS beyond one year, representing a milestone breakthrough in RAS-targeted therapy.</p><p>Oppenheimer raised its price target from $165 to $195 while maintaining an Outperform rating. The analyst consensus mean target stands at $184.29 with an average Buy rating. The company is also advancing daraxonrasib into first-line treatment and combination therapy trials, broadening its commercial outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1143599581","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143599581","pubTimestamp":1780339997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 2, Revolution Medicines rose 5.11% in regular trading, trading at approximately $165.45/share, with trading volume of $7.53 billion. The stock continued its upward momentum following landmark...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"动向提示|Revolution Medicines常规交易上涨5.11%，ASCO 3期胰腺癌数据继续提振股价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On June 2, Revolution Medicines rose 5.11% in regular trading, trading at approximately $165.45/share, with trading volume of $7.53 billion. The stock continued its upward momentum following landmark Phase 3 clinical data presented at the ASCO annual meeting.The company's pivotal RASolute 302 trial enrolled 500 previously treated metastatic pancreatic ductal adenocarcinoma patients. Results showed daraxonrasib doubled median overall survival to 13.2 months versus 6.6 months for chemotherapy, while progression-free survival improved from 3.5 to 7.3 months. The data was simultaneously published in The New England Journal of Medicine. This marks the first time a second-line pancreatic cancer therapy has extended median OS beyond one year, representing a milestone breakthrough in RAS-targeted therapy.Oppenheimer raised its price target from $165 to $195 while maintaining an Outperform rating. The analyst consensus mean target stands at $184.29 with an average Buy rating. The company is also advancing daraxonrasib into first-line treatment and combination therapy trials, broadening its commercial outlook.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143599581","isCrawlerRequest":true}